Conway Capital Management Inc. Takes $1.23 Million Position in Boston Scientific Corporation $BSX

Posted by Brenda Bartman on Aug 18th, 2026

Boston Scientific logo Conway Capital Management Inc. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 28,750 shares of the medical equipment provider’s stock, valued at approximately $1,227,000. Boston Scientific comprises about 0.5% of Conway Capital Management Inc.’s portfolio, making the stock its 25th biggest position.

A number of other large investors also recently modified their holdings of the business. Renaissance Group LLC acquired a new stake in Boston Scientific in the fourth quarter valued at $28,064,000. Y Intercept Hong Kong Ltd boosted its holdings in shares of Boston Scientific by 148.8% during the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after acquiring an additional 670,060 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab boosted its stake in Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares during the period. Meiji Yasuda America Inc bought a new stake in shares of Boston Scientific in the fourth quarter valued at about $4,708,000. Finally, S&CO Inc. bought a new stake in Boston Scientific in the 2nd quarter valued at about $7,246,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BSX has been the subject of a number of analyst reports. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a research note on Thursday, May 28th. Barclays reduced their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Wells Fargo & Company decreased their target price on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Read Our Latest Analysis on BSX

Boston Scientific Stock Performance

Shares of BSX opened at $51.46 on Tuesday. The company has a market cap of $74.58 billion, a PE ratio of 20.83, a P/E/G ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The stock has a 50-day moving average of $46.12 and a 200-day moving average of $58.81. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The stock was bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders bought 202,122 shares of company stock valued at $9,813,931. Company insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.